1. Home
  2. LPA vs ITOS Comparison

LPA vs ITOS Comparison

Compare LPA & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPA
  • ITOS
  • Stock Information
  • Founded
  • LPA 2013
  • ITOS 2011
  • Country
  • LPA United States
  • ITOS United States
  • Employees
  • LPA N/A
  • ITOS N/A
  • Industry
  • LPA
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LPA
  • ITOS Health Care
  • Exchange
  • LPA Nasdaq
  • ITOS Nasdaq
  • Market Cap
  • LPA 241.7M
  • ITOS 280.6M
  • IPO Year
  • LPA N/A
  • ITOS 2020
  • Fundamental
  • Price
  • LPA $10.02
  • ITOS $8.06
  • Analyst Decision
  • LPA
  • ITOS Strong Buy
  • Analyst Count
  • LPA 0
  • ITOS 3
  • Target Price
  • LPA N/A
  • ITOS $21.33
  • AVG Volume (30 Days)
  • LPA 24.9K
  • ITOS 470.7K
  • Earning Date
  • LPA 02-14-2025
  • ITOS 03-05-2025
  • Dividend Yield
  • LPA N/A
  • ITOS N/A
  • EPS Growth
  • LPA N/A
  • ITOS N/A
  • EPS
  • LPA N/A
  • ITOS N/A
  • Revenue
  • LPA $44,311,428.00
  • ITOS $35,000,000.00
  • Revenue This Year
  • LPA N/A
  • ITOS $271.18
  • Revenue Next Year
  • LPA N/A
  • ITOS N/A
  • P/E Ratio
  • LPA N/A
  • ITOS N/A
  • Revenue Growth
  • LPA 22.46
  • ITOS N/A
  • 52 Week Low
  • LPA $6.00
  • ITOS $7.09
  • 52 Week High
  • LPA $525.00
  • ITOS $18.75
  • Technical
  • Relative Strength Index (RSI)
  • LPA N/A
  • ITOS 54.92
  • Support Level
  • LPA N/A
  • ITOS $7.63
  • Resistance Level
  • LPA N/A
  • ITOS $8.09
  • Average True Range (ATR)
  • LPA 0.00
  • ITOS 0.31
  • MACD
  • LPA 0.00
  • ITOS 0.07
  • Stochastic Oscillator
  • LPA 0.00
  • ITOS 78.07

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Share on Social Networks: